This content was current as of the date it was released. In science and medicine, information is constantly changing and may become out-of-date as new data emerge.
NICE (The National Institute for Health and Care Excellence) is an executive non-departmental public body of the Department of Health in England, which publishes health guidelines and determines what drugs are available to patients in the UK, so their approval of the combination of venetoclax and obinutuzumab for frontline therapy gives the CLL community an excellent non-chemo choice that is already approved in the USA and several other countries. Now folks wanting to avoid chemotherapy frontline have another great option.
Here is the ABBVIE press release for more details.